<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/A40B05D5-27FA-4B57-84A3-3A31B4A08087"><gtr:id>A40B05D5-27FA-4B57-84A3-3A31B4A08087</gtr:id><gtr:name>Centre for Process Innovation Limited</gtr:name><gtr:address><gtr:line1>WILTON CENTRE , WILTON,</gtr:line1><gtr:city>REDCAR</gtr:city><gtr:postCode>TS10 4RF</gtr:postCode><gtr:region>North East</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A40B05D5-27FA-4B57-84A3-3A31B4A08087" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>A40B05D5-27FA-4B57-84A3-3A31B4A08087</gtr:id><gtr:name>Centre for Process Innovation Limited</gtr:name><gtr:address><gtr:line1>WILTON CENTRE , WILTON,</gtr:line1><gtr:city>REDCAR</gtr:city><gtr:postCode>TS10 4RF</gtr:postCode><gtr:region>North East</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>111639.0</gtr:offerGrant><gtr:projectCost>148853.0</gtr:projectCost></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EEA34757-3C76-4F96-B489-856E3A4C71E1" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>EEA34757-3C76-4F96-B489-856E3A4C71E1</gtr:id><gtr:name>AlgiPharma AS</gtr:name><gtr:address><gtr:line1>Swansea University Institute of Life Sciences
Singleton Park</gtr:line1><gtr:city>Swansea</gtr:city><gtr:postCode>SA2 8PP</gtr:postCode><gtr:region>Wales</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>0.0</gtr:offerGrant><gtr:projectCost>0.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/26B3D495-AB91-4A23-8C1C-1F99A5F9E59B"><gtr:id>26B3D495-AB91-4A23-8C1C-1F99A5F9E59B</gtr:id><gtr:firstName>Claire</gtr:firstName><gtr:surname>Bennett</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=131142"><gtr:id>6CDEF6F3-D0FE-4F53-B9E3-26953DF8DE79</gtr:id><gtr:title>ALGIFERM - Alginate Oligomers by Fermentation</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Feasibility Studies</gtr:grantCategory><gtr:grantReference>131142</gtr:grantReference><gtr:abstractText>The alginate oligomer fermentation project, ALGIFERM, translates 20 years of academic research into an industrial scale feasibility study. The Centre for Process Innovation Ltd.(UK) is leading the scale-up, whereas AlgiPharma AS (Norway) needs the final product as an Active Pharmaceutical Ingredient in its development of medicines for cystic fibrosis, COPD and chronic wounds, like diabetic foot ulcers. The biofilm disrupting and antibiotic potentiating technology that has been developed by AlgiPharma was recently published (Khan S., et al., Antimicrob Agents Chemother. 2012;56(10):5134-41). If the scale-up is successful it will facilitate the introduction of novel medicinal products to the market that will ease patient suffering and potentially reduce healthcare costs. In addition it will be a new tool in fighting multi-drug resistant bacteria. Both AlgiPharma and CPI will obtain help from SINTEF (Norway), in this innovative collaborative effort between Norwegian and English researchers.</gtr:abstractText><gtr:fund><gtr:end>2013-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2013-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>111639</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">131142</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>